Wakefield Asset Management LLLP Takes $1.20 Million Position in Catalyst Pharmaceuticals, Inc. $CPRX

Wakefield Asset Management LLLP acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 51,536 shares of the biopharmaceutical company’s stock, valued at approximately $1,203,000.

A number of other hedge funds also recently bought and sold shares of CPRX. Deerfield Management Company L.P. lifted its stake in Catalyst Pharmaceuticals by 72.8% during the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after buying an additional 2,095,291 shares in the last quarter. American Century Companies Inc. lifted its stake in Catalyst Pharmaceuticals by 43.8% during the third quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock valued at $49,805,000 after buying an additional 770,198 shares in the last quarter. Fundsmith LLP lifted its stake in Catalyst Pharmaceuticals by 24.2% during the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock valued at $66,267,000 after buying an additional 654,721 shares in the last quarter. Glenmede Investment Management LP lifted its stake in Catalyst Pharmaceuticals by 781.8% during the third quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock valued at $13,400,000 after buying an additional 603,084 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Catalyst Pharmaceuticals by 30.6% during the second quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock valued at $51,335,000 after buying an additional 554,200 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Friday, March 27th. Citigroup lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $35.00 to $31.50 in a research note on Friday, May 8th. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Stephens set a $32.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Finally, Robert W. Baird lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Three investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $32.17.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $31.18 on Friday. The firm has a market cap of $3.82 billion, a PE ratio of 17.92, a PEG ratio of 0.91 and a beta of 0.72. The firm’s 50 day moving average price is $26.14 and its 200 day moving average price is $24.33. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $32.56.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).